Outcomes

Primary end point was the occurrence of grade≥2 irAEs. The study also investigated (i) the characteristics of the irAEs (severity, time to onset, occurrence of multiple toxicities, defined as two or more grade ≥ 2 irAEs occurring in the same patient, concomitantly or not) and (ii) the survival outcomes, including progression-free survival (PFS) and overall survival (OS). Progression-free survival (PFS) was defined as the time from the first administration of ICI to progression or death. Overall survival (OS) was defined from the first administration of ICI to death from any cause. Patients were monitored from the start of the treatment until last follow-up or death.